Dr. Susan M. O'Brien, MD

Dr. O'Brien practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Dr. O'Brien's NPI, 1669577276, was assigned on September 14, 2006. Dr. O'Brien graduated from Rutgers New Jersey Medical School in 1980. Dr. O'Brien's Texas license number on file is H3130.

Dr. O'Brien's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Dr. O'Brien's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. Dr. O'Brien is also affiliated with Eisenhower Health. The medical group on file is UCI Health Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. O'Brien practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. O'Brien's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. O'Brien is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. O'Brien's licenses on file in 3 states: Texas, California and New Jersey.

Dmand AI lists chronic leukemia, lymphoma and multiple myeloma among the conditions Dr. O'Brien treats.

CMS data shows 240 Medicare services from Dr. O'Brien across 4 procedure codes in 2024, for 85 Medicare patients. Medicare paid $9,700 for them. Every service was in an office.

CMS counts 85 Medicare patients who saw Dr. O'Brien in 2024. The largest group is 65 to 74, with 40 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.33, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. O'Brien's median patient age at 68, with 45% women.

In 2024, Dr. O'Brien wrote 180 Medicare Part D claims for 25 patients. 21% of them were for generic drugs. CMS names the drug for 149 of them, across 6 drugs with 11 or more claims each, at $1,882,458 in total drug cost. In 2023, CMS named 95 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. O'Brien for performance year 2024, reported through an alternative payment model (APM). Dr. O'Brien accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. O'Brien as offering telehealth.

Dmand AI links 777 papers to Dr. O'Brien, published from 2002 to 2021. 2013 was the busiest year, with 39. The most frequent topics are Leukemia, Lymphocytic, Chronic, B-Cell, Antineoplastic Combined Chemotherapy Protocols and Antineoplastic Agents. Dr. O'Brien has published most often in Cancer. Dr. O'Brien's most frequent co-authors are Hagop M. Kantarjian, MD, Michael J. Keating, MD and William G. Wierda, MD, PhD.

Dmand AI links Dr. O'Brien to 12 clinical trials, 8 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Leukemia, Lymphocytic, Chronic, B-Cell, Burkitt Lymphoma and Lymphoma, Follicular. M.D. Anderson Cancer Center sponsors the most, 5. Open Payments lists research payments to Dr. O'Brien that name 2 trials.

CMS Open Payments shows 487 general payments to Dr. O'Brien from 31 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 80% of the total. Abbvie Inc. paid the most, $111,869. It also lists 27 research payments totaling $38,094 from 2016 to 2023, naming 2 clinical trials.

Dmand AI lists 5 awards for Dr. O'Brien, most recently Giants of Cancer Care: Leukemia in 2021.

Dr. O'Brien graduated from Rutgers New Jersey Medical School in 1980. Dr. O'Brien is a member of AACR, ASCO and ASH.

Dr. O'Brien is in network with 8 carriers, including Elevance, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.